Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We have talked about this before, the timing of Qtrly announcement indicates likely message.
Monday 8:30am pre market announcement.
Ie, up we go
RVL
"Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's fourth quarter and year-end 2014 financial results will be released on Monday, March 16, 2015. Company management will host a conference call on Monday, March 16, 2015, at 8:30 a.m. Eastern Time to discuss the financial results and other recent corporate highlights."
Thank you for your insightful, fact based comment.
We can hear on APRI Bio website
"A live audio webcast of the presentation can be accessed via the Investors section of the Company's website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 90 days following the presentation."
RVL
North,
thanks for posting this.
I missed it.
Note,
Author, Roland Perry is a familiar name
RVL
It means that I doubt the effectiveness of Dhea as an anti aging product or cure for cancer,...........
It is a known precursor for estrogen and testosterone.
Sarissa is certainly an activist in moving companies forward
RVL
"Sarissa Capital Management LP, Ariad Pharmaceuticals' (ARIA +6.9%) largest shareholder with a 6.87% stake, starts a proxy battle demanding the retirement of CEO and principal founder Harvey Berger and the removal of board member Wayne Wilson. The hedge fund will attempt to unseat both men at the company's annual meeting in June because its negotiations with other board members to force Mr. Berger out have reached an impasse."
Meco,
I'm with you.
What CC?
RVL
Value,
Thanks for the technical analysis.
You're slowly teaching me/us.
Much better than my analysis of "yeah, we are up a lot".
RVL
Recordati,
Billion dollars in Revenue, strong increasing Profitability and the first thing they talk about in Management comments is Vitaros.
Recordati financials out:
Note Management comments
RVL
RECORDATI : PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT
PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT, SALES +4.9%, OPERATING INCOME +18.2% AND NET INCOME +20.6%.
Consolidated revenue € 987.3 million, + 4.9%.
EBITDA(1) € 273.8 million, + 19.0%
Operating income € 231.0 million, + 18.2%.
Net income € 161.2 million, + 20.6%.
Net financial position(2): net debt of € 186.0 million.
Vitaros®, an innovative product for the treatment of erectile dysfunction licensed in from Apricus Biosciences.
Orphan drug designation granted in the U.S.A. to Carbaglu® for the treatment of organic acidemias.
PSD502(TM), a new product for the treatment of premature ejaculation licensed in from Plethora Solutions.
NX-1207 phase III European clinical trial prematurely interrupted.
2015 targets and plan for 2017.
Milan, 12 February 2015 - The Board of Directors of Recordati S.p.A. examined the preliminary consolidated results for 2014 and the group's development strategies and objectives for the 2015-2017 period. The company's definite consolidated annual financial reports will be submitted to the Board for approval on 4 March 2015.
Financial highlights
Consolidated revenue for the full year 2014 is € 987.3 million, up by 4.9% compared to the preceding year. International sales grow by 7.8%.
EBITDA(1), at 27.7% of sales, is € 273.8 million, an increase of 19.0% over the preceding year.
Operating income, at 23.4% of sales, is € 231.0 million, an increase of 18.2%.
Net income, at 16.3% of sales, is € 161.2 million, an increase of 20.6% over 2013.
Net financial position(2) at 31 December 2014 records a net debt of € 186.0 million. Shareholders' equity increases to € 787.4 million.
(1) Earnings before interest, taxes, depreciation and amortization.
(2) Cash and short-term financial investments less bank overdrafts and medium/long-term loans which include the measurement at fair value of hedging derivatives (fair value hedge).
Management comments
"During the year just ended important initiatives were undertaken for the future development of the company and significant group margin improvement was obtained", declared Giovanni Recordati, Chairman and CEO. "In February an exclusive license agreement was entered into with Apricus Biosciences Inc. for the marketing and sales of Vitaros® (alprostadil), an innovative topical product for the treatment of erectile dysfunction, in certain European countries, Russia, Ukraine and the Commonwealth of Independent States (C.I.S.), Turkey and certain African countries. In July the U.S. Food and Drug Administration (FDA) granted approval of Orphan Europe's request for orphan drug designation for the use of Carbaglu® (carglumic acid) in the treatment of organic acidemias (OAs). In September a license agreement with Plethora Solutions Limited and Plethora Solutions Holdings Plc for the commercialization of PSD502(TM) (Fortacin), a topical spray formulation of lidocaine and prilocaine for the treatment of premature ejaculation, in Europe, Russia, Commonwealth of Independent States (C.I.S.), Turkey and certain countries in North Africa was signed. At the end of September Erytech Pharma, a French biopharmaceutical company with which our subsidiary Orphan Europe has an exclusive agreement for the commercialization and distribution in Europe of Graspa®, reported positive top-line phase III results from its clinical study with this product in acute lymphoblastic leukemia (ALL) in frail patients.In view of the results, communicated by Nymox, of the US phase III clinical trials involving the use of NX-1207 in benign prostatic hyperplasia, which showed no significant improvement over placebo, and after profound evaluation over the last months, we decided to prematurely interrupt the European clinical trial before having reached the expected target of 340 patients."
"In the future we expect to further improve on the profitability margins achieved in 2014" continued Giovanni Recordati. "In 2015 our targets are to reach sales of more than € 1,000 million, EBIT of around € 250 million and net income of € 175 million. For the coming years we will continue our growth strategy through the development of our current product portfolio and through acquisitions and for 2017 we expect to obtain revenues of around € 1,150 million with an EBIT margin of between 25 and 26% and a net income margin of between 17 and 18%."
Declaration by the Manager responsible for preparing the Company's financial reports
The manager responsible for preparing the company's financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance, that the accounting information contained in this press release corresponds to the document results, books and accounting records.
Conference call
Recordati will be hosting a conference call today 12 February 2015 at 4.00 pm Italian time (3.00 pm London time, 9.00 am New York time). The dial-in numbers are:
Italy +39 02 8058811, toll free 800 213 858
UK +44 1 212818003, toll free 800 0156384
USA +1 718 7058794, toll free 855 2656959
France +33 170918703
Germany +49 65 255114451
Callers are invited to dial-in 10 minutes before conference time. If conference operator assistance is required during the connection please digit * followed by 0 or call +39 02 8061371. A recording of the conference call will be placed on the website www.recordati.com.
A set of slides which will be referred to during the call will be available on our website www.recordati.com under Investors/Company Presentations.
Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2013 was € 941.6 million, operating income was € 195.4 million and net income was € 133.7 million.
For further information:
Recordati website: www.recordati.com
Investor Relations Media Relations
Marianne Tatschke Studio Noris Morano
(39)0248787393 (39)0276004736, (39)0276004745
e-mail: inver@recordati.it e-mail: norismorano@studionorismorano.com
Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.
PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROV
Feb 12, 2015
HUG#1894029
Note: RPRX is on list
Pfizer (PFE) Stock Dips Today Amid Reports of More Acquisitions
BYAndrew MeolaFollow | 02/06/15 - 09:57 AM EST|
submit to reddit CommentLink
Stocks in this article: PFE
Find out if (PFE) is in Cramer's Portfolio.
NEW YORK (TheStreet) -- Shares of Pfizer (PFE - Get Report) were down 0.55% to $32.81 in morning trading Friday amid reports that the pharmaceutical giant could pursue more acquisitions after its $17 billion purchase of Hospira (HSP) .
Pfizer unsuccessfully sought a nearly $120 billion merger with AstraZeneca (AZN) last year, and its acquisition of Hospira comes at just a fraction of that cost. Pfizer therefore has room to make more acquisitions, and CEO Ian Read said the company continues to look at more opportunities, according to Bloomberg.
Kevin Kedra, an analyst at Gabelli & Co., believes that a Pfizer deal for Actavis (ACT) , which is closing its own $66 billion purchase of Botox-maker Allergan (AGN) , could fill the rest of Pfizer's needs.
What happens if Pfizer buys ACT?
My intention was to make statement that those two companies have done their homework, smarter than me, and invested.
Ie. Makes me feel good about my investment
From the Seeking Alpha article on 1/29:
"Due to the presence and involvement of Takeda and Sandoz - we literally don't feel the need to spend an undue amount of time, effort and writing space in analyzing the Vitaros® effectiveness and sales potential. In sum, investors have to ask, do they have the capabilities to better analyze the sales potential of Vitaros® thenTakeda and/or Sandoz?"
I happily outsource the expertise in determining the potential for sales and profitability for Vitaros.
RVL
I didn't see any mention of this Seeking Alpha article
Fyi
Rvl
http://seekingalpha.com/instablog/295897-roland-rick-perry/3690646-apricus-biosciences-whats-wrong-with-this-picture
sci101,
Thanks for the heads up up, I like the quote:
"In total, Takeda’s ambition is to double its revenue over the next five years. “We will continue to put substantial resources behind our primary care business,” notes Hiro Fukutomi, managing director of Takeda UK. Evidence to that effect is the recent launch of two products into the UK primary care market: Vipidia (alogliptin) for diabetes and Vitaros (alprostadil cream) for erectile dysfunction."
You don't make that statement if sales are bad.
RVL
Ok, I am not happy with PPS. BUT,
Really,
Fire people in roles at APRI that many have complained about on this Board of for years.
Hire the Senior VP of development of a company that has gone from PPS 12/13 - $2.30 to 12/14 - $9.40 and we still aren't pleased with changes made in management?
RVL
Dorsey at PTX,
PPS 12/13 - $2.30
12/14 - $9.40
Works for me
RVL
And 375000 shares again just after 3pm
Ok, here we go.
375,000 shares purchased @2:14pm today
So, PPS goes down throughout the day on higher than normal volume. A single purchase of 180,000 shares at $1.28 at 2:30pm doesn't move PPS, and then PPS continues down.
Total shares traded 383k.
How does this occur without manipulation?
Also, appears someone ramping up their rate of loading up.
Impending event?
Or the beginning of the methodical ride back up to respectable PPS?
Casino,
I think the answer is,
The reason to a pre-market Qtrly in a and present at 3 conferences over the next few weeks is unlikely to be bad news or no positive news of substance
RVL
Thanks DG,
The reason to a pre-market Qtrly in a and present at 3 conferences over the next few weeks is unlikely to be bad news or no positive news of substance
RVL
Apricus Biosciences to Present at Three Upcoming Investor Conferences in November and December of 2014
All Presentations Will be Available Via Webcast
SAN DIEGO, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a developer of biopharmaceutical therapeutics for urology and rheumatology disorders, today announced that members of senior management will present at the following three investor conferences, each of which will be webcast live and for replay at http://www.apricusbio.com/investor-relations/presentations/.
I am not going to research this to disagree. But, I do recall after hours and during trading session announcements.
Next Monday at 8:30am est. PRE-market. Must be good news.
I signed
Here we go with media attention.
Watch this parody Viagra ad by "Even the Score".
It's hilarious and on you Tube.
http://eventhescore.org
I couldn't disagree more about impact of theses public hearings with FDA about women's sexual "rights" to have Viagra like products and impact on speed to approval and The attention of media and impact on PPS.
Just look at Ebola hype and speed up of approval process and the PPS of Ebola stocks
I hope Women's rights group start protesting for equality for product R&D and approval and access.
Just my opinion.
RVL
I am going to try. But, will be in and out with attendance
Watching trades, I think someone has insight and confidence and taking advantage of low PPS in a systematic fashion. And for the first time in years, it not though shorting
A LOT.
What is the next stock your going to sell out of?
Savin4,
Nice summary.
I have been absent from this Board for a bit.
Your statement that "Bottom line - bashing management and worry-mongering doesn't create shareholder value " is exactly the reason many are advocating for their position. To ensure PPS stays under control.
I will look in again in a few months.
I believe it's like convincing a Stump to change it's position.
The Stump ain't moving no matter how effective you are at stating your position.
RVL
I googled, cut, and pasted.
I think it is merely news picked up by TMZ.Net with "tenders info" as networking vehicle.
I am assuming this is a result of increased awareness efforts of APRI.
Does anyone have insight?
Ok, I am usually the last to know here but.....
RVL
[October 05, 2014]
United States : APRICUS to launch VITAROS topical cream through marketing partners [TendersInfo (India)]
(TendersInfo (India) Via Acquire Media NewsEdge) San Diego's pharmaceutical company Apricus Biosciences is exploring solutions for unfulfilled medical needs.
The company aims to boost sexual health and especially eyes the untreated erectile dysfunction market.
Men who cannot take oral medication or have diseases that may prevent them from other treatments now have an alternative with Apricus's lead product, Vitaros, which is a topical cream to treat erectile dysfunction.
The company has won approval for the product's use in Canada and Europe..
Apricus will launch Vitaros through its marketing partners, including Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle.
(c) 2014 Euclid Infotech Pvt. Ltd. Provided by SyndiGate Media Inc. (Syndigate.info).
[ Back To TMCnet.com's Homepage ]
SB,
You are right we have Institutional investors BUT.......
As of now, if I were an Institutional Investor I would be the 5th largest. And I am hardly a big time individual investor.
They haven't put large amounts of money in this stock and, in general, they won't (and should not) put their money behind a high risk stock that is susceptible to manipulation.
A higher PPS hinders and higher volume of trades which hinders manipulation.
I am sure you agree with that concept.
If not, it's ok with me.
It's only my opinion. And you have a different one.
RVL
Are you squeezed today?